GLP-1RA与DPP-4i使用及2型糖尿病高钾血症和RAS阻断剂停药率
这项在瑞典斯德哥尔摩地区开展的队列研究纳入2008年1月1日至2021年12月31日期间启动GLP-1RA或DPP-4i治疗的2型糖尿病成人,比较两组高钾血症发生率及基线使用RASi者的停药率。共纳入33 280人(GLP-1RA 13 633人,DPP-4i 19 647人)。与DPP-4i相比,GLP-1RA使用与任何高钾血症(HR 0.61;95%CI 0.50-0.76)及中重度高钾血症(HR 0.52;95%CI 0.28-0.84)发生率较低相关,并与RASi停药率较低相关(HR 0.89;95%CI 0.82-0.97)。作者认为GLP-1RA治疗可能使指南推荐药物得到更广泛使用。
要点
- 与DPP-4i相比,GLP-1RA使用与任何高钾血症(血钾>5.0 mEq/L)发生率较低相关(HR 0.61;95%CI 0.50-0.76)。
- 与DPP-4i相比,GLP-1RA使用与中重度高钾血症(血钾>5.5 mEq/L)发生率较低相关(HR 0.52;95%CI 0.28-0.84)。
- 在基线使用RASi的21 751人中,GLP-1RA vs DPP-4i与RASi停药率较低相关(HR 0.89;95%CI 0.82-0.97)。
- 结果在年龄、性别、心血管合并症和基线肾功能各分层中一致,意向性治疗分析结果亦一致。
适用人群与场景
- 2008年1月1日至2021年12月31日期间在瑞典斯德哥尔摩地区启动GLP-1RA或DPP-4i治疗的2型糖尿病成人。
- 共33 280人,其中GLP-1RA组13 633人,DPP-4i组19 647人;平均(SD)年龄63.7(12.6)岁;男性19 853人(59.7%)。
- 中位(IQR)治疗时间3.9(1.0-10.9)个月。
诊断标准与关键阈值
- 任何高钾血症定义为血钾>5.0 mEq/L。
- 中重度高钾血症定义为血钾>5.5 mEq/L。
研究设计与关键结果
- 研究类型:队列研究;纳入瑞典斯德哥尔摩地区2008年1月1日至2021年12月31日启动GLP-1RA或DPP-4i治疗的2型糖尿病成人33 280人。
- 与DPP-4i相比,GLP-1RA使用与任何高钾血症发生率较低相关(HR 0.61;95%CI 0.50-0.76)。
- 与DPP-4i相比,GLP-1RA使用与中重度高钾血症发生率较低相关(HR 0.52;95%CI 0.28-0.84)。
- 基线使用RASi的21 751人中,1381人停药;GLP-1RA vs DPP-4i与RASi停药率较低相关(HR 0.89;95%CI 0.82-0.97)。
- 结果在意向性治疗分析及年龄、性别、心血管合并症、基线肾功能各分层中一致。
- 分析采用逆概率治疗加权平衡70余个已识别混杂因素,并用边际结构模型估计符合方案HR。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,GLP-1RA治疗可能使指南推荐药物得到更广泛使用,并可能有助于改善该人群的临床结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Hyperkalemia is a common complication in people with type 2 diabetes (T2D) that may limit the use of guideline-recommended renin-angiotensin system inhibitors (RASis). Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) increase urinary potassium excretion, which may translate into reduced hyperkalemia risk.
OBJECTIVE: To compare rates of hyperkalemia and RASi persistence among new users of GLP-1RAs vs dipeptidyl peptidase-4 inhibitors (DPP-4is).
DESIGN, SETTING, AND PARTICIPANTS: This cohort study included all adults with T2D in the region of Stockholm, Sweden, who initiated GLP-1RA or DPP-4i treatment between January 1, 2008, and December 31, 2021. Analyses were conducted between October 1, 2023, and April 29, 2024.
EXPOSURES: GLP-1RAs or DPP-4is.
MAIN OUTCOMES AND MEASURES: The primary study outcome was time to any hyperkalemia (potassium level >5.0 mEq/L) and moderate to severe (potassium level >5.5 mEq/L) hyperkalemia. Time to discontinuation of RASi use among individuals using RASis at baseline was assessed. Inverse probability of treatment weights served to balance more than 70 identified confounders. Marginal structure models were used to estimate per-protocol hazard ratios (HRs).
RESULTS: A total of 33 280 individuals (13 633 using GLP-1RAs and 19 647 using DPP-4is; mean [SD] age, 63.7 [12.6] years; 19 853 [59.7%] male) were included. The median (IQR) time receiving treatment was 3.9 (1.0-10.9) months. Compared with DPP-4i use, GLP-1RA use was associated with a lower rate of any hyperkalemia (HR, 0.61; 95% CI, 0.50-0.76) and moderate to severe (HR, 0.52; 95% CI, 0.28-0.84) hyperkalemia. Of 21 751 participants who were using RASis, 1381 discontinued this therapy. The use of GLP-1RAs vs DPP-4is was associated with a lower rate of RASi discontinuation (HR, 0.89; 95% CI, 0.82-0.97). Results were consistent in intention-to-treat analyses and across strata of age, sex, cardiovascular comorbidity, and baseline kidney function.
CONCLUSIONS: In this study of patients with T2D managed in routine clinical care, the use of GLP-1RAs was associated with lower rates of hyperkalemia and sustained RASi use compared with DPP-4i use. These findings suggest that GLP-1RA treatment may enable wider use of guideline-recommended medications and contribute to clinical outcomes in this population.
参考来源
- Huang T, Bosi A, Faucon AL, et al. GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes. JAMA Intern Med. 2024. PMID: 39133509. doi:10.1001/jamainternmed.2024.3806
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。